#fastingdiet #type2diabetes #intermittentfasting
In a study published in the journal JAMA Network Open, researchers evaluated the effect of the 5:2, that is 2 non-consecutive fasting days and 5 days of habitual intake per week, and meal replacement diet on glycemic control among patients with early type 2 diabetes compared with metformin and empagliflozin.
According to the International Diabetes Federation in 2021, 537 million adults worldwide have diabetes, affecting roughly 1 in 10 adults.
Overweight and obesity are major risk factors for type 2 diabetes, and appropriate weight loss can improve glycemic control and reduce the need for antidiabetic medications. However, achieving weight loss can be challenging, requiring strategies like meal replacement (MR) or dietary restriction which involves substituting prepackaged food or beverages for one or more meals to provide energy.
The 5:2 intermittent fasting diet, which includes two non-consecutive fasting days (with one-fourth the usual energy intake) and five days of regular eating per week, has shown promise. Previous studies found that a 12-month 5:2 intermittent fasting diet significantly reduced HbA1c levels in overweight or obese patients with type 2 diabetes, compared to a continuous energy restriction diet.
Check full updates on Medical Dialogues
Also check out -
Medical Dialogues Academy, a renowned academic wing of Medical Dialogues - India's premier health and news online portal, proudly presents this comprehensive course tailored for healthcare professionals eager to delve into the realm of medical journalism.
🔗 Enroll Today: [ Ссылка ]
📚 Explore More With Us:
📌 Medical Content Writing: [ Ссылка ]
📌 Certificate Course in Pharmaceutical Medico-Marketing: [ Ссылка ]
Join us on this enlightening journey and become a part of a community pushing the boundaries of healthcare communication and reporting.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
LinkedIn: [ Ссылка ]
Website: [ Ссылка ]
